Our results emphasize the critical role of DR3 as a modulator of ILC2 effector functions, provide new insights into the role of DR3 in VAT-derived ILC2s and establish DR3 agonist treatment as a promising novel therapeutic avenue to prevent and treat T2DM. This evidence concerns the gene TNFRSF25 and type 2 diabetes mellitus.